Navigation Links
BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
Date:2/12/2013

BOULDER, Colo., and SAN FRANCISCO, Feb. 12, 2013 /PRNewswire/ -- BiOptix in conjunction with Molecular Med TRI-CON 2013 will officially announce the expansion of the BiOptix Innovators Program, a unique-to-the-industry "try before you buy" instrument demo program that encourages researchers and institutions to become acquainted with the new BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology. 

During the event, Ken Wilczek , Vice President of Sales and Marketing for BiOptix remarked: "We are actively seeking and qualifying researchers and institutions who would like to experience a new way of evaluating and purchasing an SPR instrument."  "Through the marriage of excellent customer service and world-class technology, BiOptix aims to simplify the SPR instrument evaluation process, building a true partnership with scientific researchers to demonstrate the capabilities of the 404pi, a 21st century benchmark for new and innovative label-free SPR instrumentation."  "Quite simply, this is not your father's SPR instrument—the BiOptix 404pi will change how you think and work with SPR." continued Wilczek.  

Additional details about the BiOptix Innovators Program, including how you or your institution can request a demo of the BiOptix 404pi can be found at:  http://www.bioptix.com/products/innovators-program or by contacting BiOptix at:  303-545-5550 x 125.

In addition to Molecular Med TRI-CON 2013, BiOptix will be highlighting the 404pi at the following events during the first half of 2013:

  • PepTalk 2013 – The Protein Science Week
  • BioPhysical Society 57th Annual Meeting
  • IBC's Biopharmaceutical Development & Production Week
  • US HUPO
  • AACR — The American Association for Cancer Research
  • 9th Annual Pegs — The Essential Protein Engineering Summit
  • 2013 Merck Technology Symposia
  • TIDES 2013 — Oligonucleotide and Peptide Research, Technology and Product Development
  • 2013 Bristol-Myers Squibb Vendor & Technology Symposia

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
3. OrbusNeich Announces Favorable Ruling From the European Patent Office
4. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
5. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
6. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Second Quarter
7. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
8. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
9. Depomed Announces Appointment of Vicente J. Anido, Jr., Ph.D. to Board of Directors, and Retirement of Directors Julian N. Stern and Craig R. Smith, M.D.
10. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
11. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):